Switzerland

Switzerland in 2026: swissdamed Registration and a PMS Review

By Kieran Redington, Founder of MedFortis Published 30 October 2026 ~6 min read

Switzerland has been busy this year. Since 1 July 2026, devices sold there have to be registered in swissdamed, the Swiss device database, with a transition period that ends on 31 December. And in April, Swissmedic wrote to every Swiss manufacturer and Swiss authorised representative to say it would be checking post-market surveillance files again. If you sell into Switzerland, both are worth a look before the end of the year.

Why Switzerland has its own database

Switzerland isn't in the EU, and since the mutual recognition agreement for medical devices lapsed in 2021, it has run its own regime under the Medical Devices Ordinance (MedDO). Swiss rules follow the EU MDR closely, but Swiss registration happens in Swiss systems. EUDAMED doesn't cover it, so swissdamed is the Swiss counterpart. Manufacturers outside Switzerland need a Swiss authorised representative, who is responsible for formal and safety matters when the device is placed on the Swiss market.

swissdamed registration

From 1 July 2026, devices, systems and procedure packs have to be registered in the swissdamed UDI devices module. This replaces the older notification procedures. Devices placed on the Swiss market after 1 July have a transition period to complete registration, which ends on 31 December 2026.

Two details are easy to miss:

The Swiss deadline comes about a month after the EU's own EUDAMED device registration started, so many teams are doing both at once. Our guide to EUDAMED legacy device registration covers the EU side.

Swissmedic's 2026 PMS review

On 23 April 2026, Swissmedic sent an information letter to all Swiss manufacturers and Swiss authorised representatives. It announced a focus campaign: Swissmedic will pick a number of Class IIa, IIb and III devices on the Swiss market at random and ask for their post-market surveillance documentation.

This isn't the first time. A similar campaign in 2024 found that many manufacturers struggled to meet these obligations in full, and Swissmedic published the results. The letter is a reminder that the obligations in the MedDO are being checked:

You don't need to reply to the letter. If one of your devices is selected, Swissmedic will write to you separately. It also points out that it can inspect manufacturers and Swiss authorised representatives at any time, campaign or not.

Getting your file ready

If Swissmedic asked for your documentation next week, could you send it? For each Class IIa, IIb and III device you sell in Switzerland, check that:

The third point is where files are often thin. A PMS plan that says "we monitor regulator databases" needs evidence behind it: what was checked, when, and what you concluded.

Where MedFortis fits

MedFortis watches recalls and safety notices from Swissmedic alongside the FDA, MHRA, Health Canada, EUDAMED and other national regulators, for your devices and similar ones. Each new signal is assessed by your team and the decision is recorded with its reason. When it's time for a PSUR, or a regulator asks for your file, the external data and the record of what you did about it are already there, and the data annex for your report can be produced on demand.

See what's been published about your devices

Book a free 30-minute demo. We'll run MedFortis on your device lines and show you their recalls and safety notices across Switzerland, the EU, the UK and North America.

Book a Demo →

Key takeaways

  • Device registration in swissdamed has been mandatory since 1 July 2026. The transition period ends on 31 December 2026.
  • Devices involved in a serious incident, field safety corrective action or trend report must be registered immediately.
  • Swissmedic is reviewing post-market surveillance files for randomly selected Class IIa, IIb and III devices in 2026.
  • Make sure your plan, reports and evidence of what you monitored are ready to send, including through your Swiss authorised representative.
This article is provided for general information only and is not legal or regulatory advice. Regulatory requirements are summarised and paraphrased; always refer to the official texts and guidance, and consult a qualified regulatory professional for your specific devices and markets.